Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | XDH | P47989 | 1/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.36 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.34 |
| ▸ | CCR4 | P51679 | 1/20 | 0.32 |
| ▸ | ABL1 | P00519 | 1/20 | 0.31 |
| ▸ | RAD52 | P43351 | 1/20 | 0.31 |
| ▸ | RIN1 | Q13671 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31380770 | 1.00 | XDH (0.37) | XDHCYP1A2PDPK1CYP2C19CCR4 | |
| SCHEMBL16549309 | 0.81 | CDK2 (0.41) | XDHKDM4E | |
| SCHEMBL22700363 | 0.79 | MEN1 (0.37) | CYP1A2PDPK1CYP2C19CCR4ABL1 | |
| SCHEMBL19978884 | 0.79 | PDPK1 (0.36) | CYP1A2PDPK1CYP2C19ABL1RAD52 | |
| SCHEMBL9503831 | 0.79 | PDPK1 (0.36) | CYP1A2PDPK1CYP2C19ABL1RAD52 | |
| Methylguanine SCHEMBL1336757 | 0.79 | CDK1 (0.41) | PDPK1 | |
| Methylguanine SCHEMBL29968306 | 0.79 | CDK1 (0.41) | PDPK1 | |
| SCHEMBL18961720 | 0.76 | GAA (0.35) | CYP1A2PDPK1CYP2C19MAPTKDM4E | |
| SCHEMBL16549303 | 0.76 | PIN1 (0.44) | SMN1; SMN2KDM4E | |
| SCHEMBL6268748 | 0.76 | CDK1 (0.43) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3778604-B1 | LRRK2 INHIBITORS AND METHODS OF MAKING AND USING THE SAME | DANA FARBER CANCER INST INC (US) | 2026-01-07 | — | — | EP | disclosed |
| WO-2025026903-A1 | IMIDAZO PYRIMIDINE COMPOUNDS FOR THE TREATMENT OF CANCER | BAYER AKTIENGESELLSCHAFT (DE) | 2025-02-06 | — | — | WO | disclosed |
| US-20220024925-A1 | Deuterium-Substituted 7-Substituted-2-(Benzylamino)-6-Ozopurine Compounds and Uses Thereof | ACURX PHARMACEUTICALS, LLC | 2022-01-27 | — | — | US | disclosed |
| US-20220024925-A1 | Deuterium-Substituted 7-Substituted-2-(Benzylamino)-6-Ozopurine Compounds and Uses Thereof | ACURX PHARMACEUTICALS, LLC | 2022-01-27 | — | — | US | disclosed |
| CN-113563342-A | LRRK2 inhibitors and methods of making and using the same | 达纳－法伯癌症研究所公司 | 2021-10-29 | — | — | CN | disclosed |
| CN-107801397-B | LRRK2 inhibitors and methods of making and using the same | 达纳－法伯癌症研究所公司 | 2021-07-30 | — | — | CN | disclosed |
| EP-3134411-B1 | PURINE DERIVATIVES AS CD73 INHIBITORS FOR THE TREATMENT OF CANCER | BOEHRINGER INGELHEIM INT (DE) | 2021-06-30 | — | — | EP | disclosed |
| US-20210115055-A1 | LRRK2 INHIBITORS AND METHODS OF MAKING AND USING THE SAME | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2021-04-22 | — | — | US | disclosed |
| US-20210115055-A1 | LRRK2 INHIBITORS AND METHODS OF MAKING AND USING THE SAME | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2021-04-22 | — | — | US | disclosed |
| EP-3778605-A2 | LRRK2 INHIBITORS AND METHODS OF MAKING AND USING THE SAME | Dana Farber Cancer Institute, Inc. (US) | 2021-02-17 | — | — | EP | disclosed |
| WO-2018049534-A1 | NUCLEOSIDE AND NUCLEOTIDE ANALOGUES BEARING A QUATERNARY ALL-CARBON STEREOGENIC CENTER AT THE 2' POSITION AND METHODS OF USE AS A CARDIOPROTECTIVE AGENT | LCB PHARMA INC. (CA) | 2018-03-22 | — | — | WO | disclosed |
| EP-3256475-A2 | LRRK2 INHIBITORS AND METHODS OF MAKING AND USING THE SAME | Dana-Farber Cancer Institute, Inc. (US) | 2017-12-20 | — | — | EP | disclosed |
| EP-2475252-B1 | SELECTIVE ANTIBACTERIALS FOR CLOSTRIDIUM DIFFICILE INFECTIONS | GLSYNTHESIS INC (US) | 2016-11-16 | — | — | EP | disclosed |
| WO-2016130920-A2 | LRRK2 INHIBITORS AND METHODS OF MAKING AND USING THE SAME | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2016-08-18 | — | — | WO | disclosed |
| WO-2016130920-A2 | LRRK2 INHIBITORS AND METHODS OF MAKING AND USING THE SAME | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2016-08-18 | — | — | WO | disclosed |
| CN-103788160-B | (2R, 5R)-5-phosphatidyl methoxy-2-(2-substituted adenines-9-base)-2,5-dihydrofuran nucleoside analog and its production and use | 郑州大学 | 2016-07-06 | — | — | CN | disclosed |
| US-8796292-B2 | Selective antibacterials for clostridium difficile infections | GLSYNTHESIS INC. (US) | 2014-08-05 | — | — | US | disclosed |
| US-20120232077-A1 | SELECTIVE ANTIBACTERIALS FOR CLOSTRIDIUM DIFFICILE INFECTIONS | ACURX PHARMACEUTICALS, LLC | 2012-09-13 | — | — | US | disclosed |
| EP-2475252-A1 | SELECTIVE ANTIBACTERIALS FOR CLOSTRIDIUM DIFFICILE INFECTIONS | Glsynthesis Inc. (US) | 2012-07-18 | — | — | EP | disclosed |
| WO-2011031935-A1 | SELECTIVE ANTIBACTERIALS FOR CLOSTRIDIUM DIFFICILE INFECTIONS | GLSYNTHESIS INC. (US) | 2011-03-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120232077-A1 | SELECTIVE ANTIBACTERIALS FOR CLOSTRIDIUM DIFFICILE INFECTIONS | MRPL21, RPN2, ALPI | XDH 355/4885CYP1A2 293/4885PDPK1 3556/4885 |
| US-20210115055-A1 | LRRK2 INHIBITORS AND METHODS OF MAKING AND USING THE SAME | LRRK2, PARK7, PINK1 | XDH 1897/4885CYP1A2 4606/4885PDPK1 26/4885 |
| US-20220024925-A1 | Deuterium-Substituted 7-Substituted-2-(Benzylamino)-6-Ozopurine Compounds and Uses Thereof | DUT, DCTD, TPMT | XDH 75/4885CYP1A2 455/4885PDPK1 3185/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.